Associate Professor of Medicine, UCLA
Hematology
Dr. Robert A. Vescio, MD
|
|
Give Review
Robert A. Vescio, MD practices Hematology. She researched medicine at University of California San Diego School of Medicine. University of California San Diego School of Medicine is ranked 17/19 in Research/PrimaryCare. She over the years received 6 awards: "America's Top Doctors", "Top Doctors:LA Area", "America's Top Doctors for Cancer", "Top Doctors:Southern California", "Whos Who in Medicine and Healthcare" and "Super Doctor". Robert Vescio is a published doctor. She has 77 publications published. The most current publication "Recent advances in the treatment of multiple myeloma." She is registered with Medicare and accepts Medicare payments.
Publications
- Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple my...
- A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma.
- Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.
- A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.
- Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.
- Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
- Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis.
- The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
- Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma.
- A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma pat...
- Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
- Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethason...
- An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma.
- Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma.
- Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
- Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
- Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases.
- A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory mul...
- A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
- Advances in the diagnosis of multiple myeloma.
- Analysis of multiple myeloma third complementarity-determining regions reveals characteristics of prenatal B cells.
- Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.
- Interleukin-6 inhibits apoptosis of malignant plasma cells.
- Silicone gel implants and monoclonal gammopathies: three cases of multiple myeloma and the prevalence of multiple myeloma and monoclonal gammopathy of undetermined sig...
- Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma.
- Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide.
- Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function.
- Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma.
- Multiple myeloma and chronic lymphocytic leukemia.
- Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.
- Autologous transplantation. Purging and the impact of minimal residual disease.
- Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma.
- BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
- Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine i...
- Cytomegalovirus infection following transplantation of autologous CD34-selected progenitor cells.
- A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
- The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
- Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple ...
- Frequent demonstration of human herpesvirus 8 (HHV-8) in bone marrow biopsy samples from Turkish patients with multiple myeloma (MM).
- The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group.
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and ...
- The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement.
- Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
- Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer...
- Cloning of the first invertebrate MAGE paralogue: an epitope that activates T-cells in humans is highly conserved in evolution.
- Recent advances in multiple myeloma.
- Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution.
- Human herpesvirus 8 (KSHV) contamination of peripheral blood and autograft products from multiple myeloma patients.
- The role of human herpesvirus-8 in the pathogenesis of multiple myeloma.
- Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma.
- HHV-8 infection and multiple myeloma.
- Identification of a new, unorthodox member of the MAGE gene family.
- The role of human herpesvirus-8, (HHV-8), in multiple myeloma pathogenesis.
- HHV-8 is present in multiple myeloma patients.
- HHV-8 and multiple myeloma.
- Recent advances in the treatment of multiple myeloma.
- Methylation of the p16INK4A gene in multiple myeloma.
- Multiple myeloma: the cells of origin--a two-way street.
- Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients.
- Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.
- Deletion of genetic material from a poly(ADP-ribose) polymerase-like gene on chromosome 13 occurs frequently in patients with monoclonal gammopathies.
- VH gene usage is multiple myeloma: complete absence of the VH4.21 (VH4-34) gene.
- Identification of malignant cells in multiple myeloma bone marrow with immunoglobulin VH gene probes by fluorescent in situ hybridization and flow cytometry.
- Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity.
- Multiple myeloma clones are derived from a cell late in B lymphoid development.
- The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma.
- A CD10-positive subset of malignant cells is identified in multiple myeloma using PCR with patient-specific immunoglobulin gene primers.
- In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture.
- The distinction of small cell and non-small cell lung cancer by growth in native-state histoculture.
- Cancer biology for individualized therapy: correlation of growth fraction index in native-state histoculture with tumor grade and stage.
- Correlation of histology and drug response of human tumors grown in native-state three-dimensional histoculture and in nude mice.
- A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
- Human herpesvirus 8 open reading frame 26 and open reading frame 65 sequences from multiple myeloma patients: a shared pattern not found in Kaposi's sarcoma or primary...
- The role of human and viral cytokines in the pathogenesis of multiple myeloma.
- Lack of serologic association of human herpesvirus-8 (KSHV) in patients with monoclonal gammopathy of undetermined significance with and without progression to multipl...
- Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects.
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:LA Area
- America's Top Doctors for Cancer
- Top Doctors:Southern California
- Whos Who in Medicine and Healthcare
- Super Doctor
Education
-
UCLA Medical Center -
University of California San Diego -
University of California San Diego School of Medicine
Hospital
-
Ronald Reagan UCLA Medical Center -
Cedars-Sinai Medical Center
Drug Facts
| NPI NUMBER | 1962509216 | |
| NPPES Provider LastName | VESCIO | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 900481804 | |
| NPPES Provider State | CA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 2105.0 | |
| Distinct Opioid Count | 7.0 | |
| Opioid Claim Count | 277.0 | |
| Percent Opioid Claims | 13.16 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1962509216 |
| Last Name Of The Provider | VESCIO |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
Dr. Steven A. Miles, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael T. Schmidt, DO |
|
|
Rina Kansal, MB |